Ossiam Reduces Holdings in Boston Scientific Corporation $BSX

Ossiam reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 6.0% during the 3rd quarter, Holdings Channel.com reports. The fund owned 611,448 shares of the medical equipment provider’s stock after selling 38,766 shares during the quarter. Boston Scientific comprises about 0.8% of Ossiam’s portfolio, making the stock its 18th biggest position. Ossiam’s holdings in Boston Scientific were worth $59,696,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BSX. Thematics Asset Management grew its holdings in shares of Boston Scientific by 9.6% during the third quarter. Thematics Asset Management now owns 83,346 shares of the medical equipment provider’s stock worth $8,137,000 after purchasing an additional 7,268 shares during the last quarter. Prosight Management LP purchased a new stake in shares of Boston Scientific in the 3rd quarter valued at about $7,430,000. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its holdings in shares of Boston Scientific by 14.2% in the 3rd quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 8,615 shares of the medical equipment provider’s stock valued at $841,000 after purchasing an additional 1,073 shares during the last quarter. iSAM Funds UK Ltd acquired a new stake in shares of Boston Scientific in the 3rd quarter valued at about $1,472,000. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna boosted its position in shares of Boston Scientific by 4.1% in the 3rd quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 7,058 shares of the medical equipment provider’s stock valued at $689,000 after purchasing an additional 280 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on BSX shares. Robert W. Baird cut their price target on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. The Goldman Sachs Group set a $99.00 price objective on Boston Scientific in a report on Thursday, February 5th. Oppenheimer lowered their target price on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. Stifel Nicolaus reduced their price target on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Finally, TD Cowen decreased their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $108.00.

Boston Scientific Stock Up 0.9%

BSX opened at $69.15 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific Corporation has a 12 month low of $67.56 and a 12 month high of $109.50. The stock has a market capitalization of $102.61 billion, a P/E ratio of 35.64, a P/E/G ratio of 0.96 and a beta of 0.69. The business has a 50 day simple moving average of $82.47 and a 200-day simple moving average of $93.39.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the prior year, the company posted $0.70 earnings per share. Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.50% of the stock is owned by corporate insiders.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.